US ophthalmology technology firm EyeQue has launched VisionCheck, which it says is the world’s first automated optical device allowing consumers to measure and track their refractive error
Spark Therapeutics’ gene therapy for a rare inherited sight disorder, Luxturna has been approved in Europe, but there was still no word on price from marketing partner Novartis.
Novartis’ ophthalmology division Alcon has announced plans to build a digital platform to streamline, simplify and improve cataract surgery for surgeons and patients.
Novartis is appealing against a High Court ruling that it is lawful for the NHS to prescribe Roche’s Avastin (bevacizumab) in an unlicensed use in wet age-related macular degeneration (AMD)
Ionis and Roche have struck a deal worth up to $760 million (£575 million) to develop a drug to treat advanced age-related macular degeneration (AMD), a leading cause of blindness.
England’s High Court has ruled it is lawful to use Roche’s Avastin (bevacizumab) in an unlicensed use in wet age-related macular degeneration (AMD) instead of more expensive approved drugs
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.